Bispecific CD33-CD3 Antibody Periodic Dosing for Leukemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia using bispecific antibody constructs face challenges in effectively targeting myeloid leukemic cells while minimizing toxicity to essential myeloid compartment cells, requiring a balance between treatment duration and dose to avoid severe immunologic side effects.
Innovation Solution
A bispecific single chain antibody construct with a first binding domain specific to CD33 and a second binding domain specific to CD3 is administered for a maximal period of 14 days, followed by a 14-day break, using a step dosing schedule to efficiently eliminate myeloid leukemic cells while allowing the myeloid compartment to recover.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the construct is administered continuously for an extended period to eliminate myeloid leukemic cells, then treatment efficacy is improved, but severe immunologic side effects such as cytokine release syndrome occur
Solution Approach 1:
The patent implements periodic administration of the bispecific construct with treatment cycles separated by interruption periods of at least 14 days. This periodic action allows the myeloid compartment to recover between treatments while maintaining treatment efficacy over time, avoiding continuous exposure that triggers severe immunologic side effects
Solution Approach 2:
The patent employs dynamic dosing strategies including step-wise dose escalation and individualized treatment duration adjustments based on patient response and tolerance. This dynamic approach optimizes treatment efficacy while adapting to minimize immunologic side effects in each patient
2Productivity
If the administration period is extended to maximize leukemic cell elimination, then treatment efficacy is improved, but the myeloid compartment suffers toxicity and cannot recover
Solution Approach 1:
The patent utilizes periodic treatment cycles with mandatory interruption periods of at least 14 days between construct administrations. This periodicity enables the myeloid compartment to regenerate and recover function between treatment phases, preventing cumulative toxicity while maintaining high leukemic cell elimination rates during active treatment periods
Solution Approach 2:
The patent applies partial action by limiting each treatment phase to a maximum of 14 days of continuous administration, which is sufficient to achieve significant leukemic cell reduction without causing irreversible damage to the myeloid compartment, allowing for repeated treatment cycles
3Reliability
If a continuous dosing schedule is used to maintain therapeutic levels, then treatment efficacy is improved, but immunologic side effects increase
Solution Approach 1:
The patent implements periodic administration schedules with treatment phases followed by interruption periods of at least 14 days. This periodicity maintains therapeutic efficacy during treatment phases while preventing the cumulative immunologic activation that leads to cytokine release syndrome, by allowing immune system reset between cycles
Solution Approach 2:
The patent employs preliminary dose escalation phases where the construct is introduced at low doses and gradually increased over multiple cycles before reaching full therapeutic dosage. This preliminary action allows the immune system to adapt progressively, reducing the risk of severe cytokine release syndrome when full therapeutic levels are achieved
Data Source
Figure 1
Figure 2A~3B
AI summary
The present invention provides a bispecific construct comprising a first binding domain specifically binding to CD33 and a second binding domain specifically binding to CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered for a maximal period of 14 days followed by a period of at least 14 days without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficientamount of such bispecific construct and the use of such bispecific construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia.